Brevibacterium casei AP9 Probiotic Strain for Digestive Survival
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current probiotic organisms, such as Lactobacillus strains, face challenges with poor pH and bile tolerance, limited survival in gastric and intestinal juices, and inadequate antimicrobial properties, which hinders their effectiveness in cholesterol reduction and overall probiotic performance.
Innovation Solution
The isolation and development of Brevibacterium casei AP9 MCC0012, which exhibits improved bile salt hydrolase activity, enhanced tolerance to gastric and intestinal juices, and antimicrobial properties, forming a novel probiotic composition that can be used alone or in combination with other organisms to enhance probiotic activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Lactobacillus strains are used as probiotics, then they can provide basic probiotic functions, but they suffer from poor pH tolerance, poor bile tolerance and indifferent survival in gastric and intestinal juices
Solution Approach 1:
The patent changes the species parameter from Lactobacillus to Brevibacterium casei, which inherently possesses superior pH tolerance, bile tolerance, and survival capabilities in gastric and intestinal juices. This parameter change resolves the contradiction by selecting an organism with naturally improved resistance properties while maintaining probiotic functionality.
Solution Approach 2:
The patent copies the beneficial properties of marine-derived Brevibacterium casei AP9, which has evolved natural resistance to harsh conditions. By isolating and utilizing this strain, the invention replicates the superior survival characteristics found in marine environments, overcoming the limitations of conventional Lactobacillus strains.
2Reliability
If Lactobacillus strains are used, then they can provide some probiotic activity, but they have poor adhesion property and inadequate cholesterol reducing or lipid degradation property due to production of Bile salt hydrolase (BSH)
Solution Approach 1:
The patent changes the organism parameter from Lactobacillus to Brevibacterium casei AP9, which naturally exhibits superior adhesion properties and enhanced BSH production capabilities. This parameter change simultaneously improves adhesion to intestinal mucosa, cholesterol reduction, and lipid degradation without the limitations of conventional probiotics.
Solution Approach 2:
The Brevibacterium casei AP9 strain possesses inherent self-service capabilities including natural adhesion mechanisms and constitutive BSH production that enable it to perform probiotic functions effectively without requiring combination with multiple other organisms, thereby improving reliability while reducing complexity.
3Adaptability or versatility
If multiple Lactobacillus organisms are combined in products, then they can provide diverse functions, but the product complexity increases and costs increase
Solution Approach 1:
The patent applies universality by selecting Brevibacterium casei AP9 as a single multi-functional probiotic organism that performs adhesion, cholesterol reduction, lipid degradation, and antimicrobial activities. This single strain replaces the need for combinations of 3-5 different Lactobacillus organisms, thereby maintaining diverse probiotic functions while significantly reducing product complexity.
Solution Approach 2:
The patent extracts and utilizes the essential probiotic functions from a potential multi-organism combination and concentrates them into a single superior strain of Brevibacterium casei AP9. This extraction approach maintains the versatility of probiotic functions while eliminating the complexity of combining multiple organisms.
4Reliability
If organisms with improved pH tolerance and bile tolerance are sought, then better survival in digestive juices is achieved, but the search and development process becomes more complex
Solution Approach 1:
The patent applies preliminary action by pre-selecting marine-derived Brevibacterium casei AP9, which has already evolved natural resistance to harsh conditions in its marine habitat. This preliminary selection from a proven source simplifies the screening process compared to searching through conventional environments, as the marine origin inherently provides the desired pH and bile tolerance properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Brevibacterium casei AP9 MCC0012 demonstrates improved survival and activity in harsh digestive conditions, effective bile salt tolerance, and significant cholesterol reduction capabilities, making it a superior probiotic strain for treating gastric disorders and lowering serum cholesterol levels.
Implementation Method 1
production of Bile salt hydrolase (BSH)
Data Source
AI summary
The present invention discloses a novel isolated bacterial strain exhibiting probiotic properties. More particularly, the invention discloses a probiotic composition comprising Brevibacterium casei AP9 MCC0012 having improved pH and bile tolerance and improved antimicrobial properties as well as possessing cholesterol reduction property.